Dutch single center study of ANCA tests (n 5518) betw 2012-2023; 286 (5.2%) were positive: 63% did not have AAV. ANCA+ Non-AAV pts had other CTD, neoplasia, infxn, or used specific drugs. IIF and ELISA 1st test - good negative predictive values. Performing a second test increased https://t.co/0oAhOg10VL

The 1980s quietly rewired rheumatology. Methotrexate became the anchor DMARD. APS emerged as a distinct clinical syndrome. SLE classification was standardized. Cytokine biology began pointing toward the biologic era. A decade that moved rheumatology from symptom control toward https://t.co/9NUXorQDTG

Dr John Stone grand rounds Kroc lecture #wustlRheum. Pearls: -IgG4RD can manifest as a variable vasculitis -Men have worse disease -Histology will not show necrosis or neutrophils -IgG4 levels will rise as the disease progress (>5X) -Rx with B cell therapy @alhkim @RheumNow https://t.co/GUw348OrrA

FDA Grants Fast Track Designation to treprostinil inhalation powder (Yutrepia - currently FDA approved to tx Pulm HTN) for the Treatment of Raynaud’s Phenomenon assoc w/ Systemic Sclerosis. A Phase 2a RE-WARM dose-finding study will begin October 2026. https://t.co/x4X1Ld1egZ https://t.co/GsZ9LXJjre

Listen as Dr. Catherine Bakewell discusses an important topic: Structural damage in adult patients with active psoriatic arthritis. Sponsored by Johnson & Johnson Medical Affairs https://t.co/TjicrrRSOs https://t.co/iTzsMhmvpF

Sobi Receives US FDA Fast Track Designation for pacritinib in VEXAS Syndrome. Pacritinib (Vonjo) is a kinase inhibitor (JAK2, FLT3) that is approved to treat adults with intermediate or high-risk myelofibrosis https://t.co/V7duJPyJpG https://t.co/N9rg30EA4W

Meta-analysis 24 studies (3015 hidradenitis suppurativa pts) taking IL-17 inhibitor, IBD adverse events were rare, w/ no difference in IBD risk betw IL-17i & PBO (0.23% vs 0 of 2572 vs 1066 pts respectively) thru wk 16. The reported assocn of IL-17 inhibitors w/ IBD risk is https://t.co/kDwR5Fc1zI

Difficult PsA is called ‘difficult-to-manage’ (D2M) or ‘treatment-refractory’ dz (TRD). Data from 5 Nordic PsA registries 14,362 ps, D/Cs of ≥2/≥3/≥4 b/tsDMARDs in 36%/18%/10%. Freq of D2M low 2%/3%/3%, & TRD was 1.2%/1.2%/0.8%. Female #s, depression, & opioids incr w/ # of https://t.co/FkQU5BVRn2

RCT 451 chronic LBP in general practice shows 8-wk telehealth mindfulness reduced pain intensity and interference at 6 months compared with usual care, BUT changes did not meet the prespecified mean 1-point MCID between groups. Is it worth doing? https://t.co/H4oYTeq1is https://t.co/cozq7gGnYO

Obesity isn’t just a comorbidity—it can influence inflammation, disease activity and treatment response. Join our second Tuesday Night Rheumatology webinar this month as leading experts explore the biology of fat and its impact on rheumatic disease. Register: https://t.co/jsWungkcG6

Osteoarthritis, Obesity and GLP-1s https://t.co/SGnWksQBpT https://t.co/TPxM4aj7bd

QD Clinic: Obesity: Escalate or Reassess? Dr. Mrinalini Dey, London, presents this QD Clinic as part of RheumNow's "The Obesity Imperative" presented in September 2026. https://t.co/wt5N6RZmg6 https://t.co/3EyRa1WC9U

ACP Position Statements on the Ethics of AI in Medical Practice Recently JAMA updated its guidance on artificial intelligence (AI) in medical publications. Now, the ACP has published a position paper regarding the use and ethical considerations for the use of AI in medical https://t.co/J6qgfI2Sgt

Treating Obesity is Disease-Modifying (9.4.2026) Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow. New drugs approved, new drugs halted and some drugs out of control. https://t.co/ojBOosSWMX https://t.co/K4DvUK24Pb